Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
Zacks Investment Research | Mar 17, 2019 09:22PM ET
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) announced that it has withdrawn the biologics license application (“BLA”) seeking approval for its neutropenia candidate, Rolontis. The company stated that the withdrawal is due to the FDA’s request for additional manufacturing-related data for the drug. Moreover, though the additional data ar not likely to be a major amendment to the BLA, theexpected time to gather the requested data is likely to cross the 60-day review period ending Mar 29.
Shares of Spectrum Pharma fell more than 7% in pre-market trading on Mar 15. However, the company recovered most of the loss in normal trading and closed at 2.9% down on Mar 15. The company’s shares are up 14.1% so far this year compared with the industry ’s growth of 19.1%.
Spectrum Pharma said the FDA also did not raise any concern related to the pre-clinical and clinical data submitted with the BLA or made any request to conduct additional studies. The company is in active discussion with the FDA and plans to file the updated BLA, including the requested information, as early as possible.
With the sale of the marketed portfolio in March, Spectrum Pharma has no steady product revenues. The company depends on the success of its pipeline development. Rolontis is the lead candidate, which has been evaluated for treating chemotherapy-induced neutropenia in patients undergoing myelosuppressive chemotherapy.
The BLA was based on positive data from two phase III studies, namely ADVANCE and RECOVER. In both programs, Rolontis demonstrated non-inferiority to Amgen’s (NASDAQ:AMGN) Neulasta (pegfilgrastim) in improving duration of severe neutropenia.
Apart from Rolontis, the company is developing poziotinib for the treatment of metastatic non-small cell lung cancer with EGFR exon 20 mutations. In December 2018, the company had received a setback as the FDA did not grant Breakthrough Therapy designation to the candidate.
A marketing approval to pipeline candidates is necessary for future prospects of Spectrum Pharma. With the withdrawal of Rolontis BLA, commercialization of the candidate will also be delayed.
Spectrum Pharmaceuticals, Inc. Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.